_id
69130495ccc777a4e85d7a63
Ticker
IVBXF
Name
Innovent Biologics Inc
Exchange
PINK
Address
168 Dongping Street, Suzhou, China, 215123
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.innoventbio.com
Description
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverematinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), Dupert (fulzerasib), DOVBLERON (taletrectinib), Jaypirca (pirtobrutinib), limertinib, and SYCUME (teprotumumab N01 injection). The company is also developing three new drugs, which are under regulatory review; four assets in Phase 3 and pivotal clinical trials; and 15 molecules in early clinical stage. In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Last Close
10.305
Volume
4820
Current Price
11.55
Change
1.074
Last Updated
2026-01-04T15:31:22.418Z
Image
-
Ipo Date
-
Market Cap
18625951744
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.6904166666666667
Sentiment Sources
12
Current Quarter
2025-06-30
Revenue
5953094000
Cost Of Revenue
1353562000
Gross Profit
4599532000
Operating Expenses
3825980000
Operating Income
773552000
Interest Expense
-
Pretax Income
897117000
Net Income
834321000
Eps
0.4923162278800379
Dividends Per Share
-
Shares Outstanding
1720801070
Income Tax Expense
62796000
EBITDA
1029578000
Operating Margin
12.994117008735289
Total Other Income Expense Net
123565000
Cash
9540139000
Short Term Investments
-
Receivables
1722353000
Inventories
1128113000
Total Current Assets
13092874000
Property Plant Equipment
5601765000
Total Assets
23594272000
Payables
432292000
Short Term Debt
1114591000
Long Term Debt
2263120000
Total Liabilities
9172452000
Equity
14421820000
Bs_currency_symbol
CNY
Depreciation
265990000
Change In Working Capital
-1093296000
Cash From Operations
313765000
Capital Expenditures
102576000
Cash From Investing
544790000
Cash From Financing
648420000
Net Change In Cash
3770313000
Cf_currency_symbol
-
PE
108.24
PB
1.3572221447050372
ROE
5.7851297547743625
ROA
3.53611673206107
FCF
211189000
Fcf Percent
0.03547550231862625
Piotroski FScore
3
Health Score
56
Deep Value Investing Score
7.5
Defensive Investing Score
6.5
Dividend Investing Score
3
Economic Moat Investing Score
6.3
Garp Investing Score
6.5
Growth Investing Score
5.5
Momentum Investing Score
4
Net Net Investing Score
3.5
Quality Investing Score
6.5
Value Investing Score
5.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
5953094000
Quarters > 0 > income Statement > cost Of Revenue
1353562000
Quarters > 0 > income Statement > gross Profit
4599532000
Quarters > 0 > income Statement > operating Expenses
3825980000
Quarters > 0 > income Statement > operating Income
773552000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
897117000
Quarters > 0 > income Statement > net Income
834321000
Quarters > 0 > income Statement > eps
0.4923162278800379
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
1694685149
Quarters > 0 > income Statement > income Tax Expense
62796000
Quarters > 0 > income Statement > EBITDA
1029578000
Quarters > 0 > income Statement > operating Margin
12.994117008735289
Quarters > 0 > income Statement > total Other Income Expense Net
123565000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
9540139000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
1722353000
Quarters > 0 > balance Sheet > inventories
1128113000
Quarters > 0 > balance Sheet > total Current Assets
13092874000
Quarters > 0 > balance Sheet > property Plant Equipment
5601765000
Quarters > 0 > balance Sheet > total Assets
23594272000
Quarters > 0 > balance Sheet > payables
432292000
Quarters > 0 > balance Sheet > short Term Debt
1114591000
Quarters > 0 > balance Sheet > long Term Debt
2263120000
Quarters > 0 > balance Sheet > total Liabilities
9172452000
Quarters > 0 > balance Sheet > equity
14421820000
Quarters > 0 > balance Sheet > currency_symbol
CNY
Quarters > 0 > cash Flow > net Income
834321000
Quarters > 0 > cash Flow > depreciation
265990000
Quarters > 0 > cash Flow > change In Working Capital
-1093296000
Quarters > 0 > cash Flow > cash From Operations
313765000
Quarters > 0 > cash Flow > capital Expenditures
102576000
Quarters > 0 > cash Flow > cash From Investing
544790000
Quarters > 0 > cash Flow > cash From Financing
648420000
Quarters > 0 > cash Flow > net Change In Cash
3770313000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
0.4923162278800379
Quarters > 0 > ratios > PB
1.3572221447050372
Quarters > 0 > ratios > ROE
5.7851297547743625
Quarters > 0 > ratios > ROA
3.53611673206107
Quarters > 0 > ratios > FCF
211189000
Quarters > 0 > ratios > Piotroski FScore
3
Quarters > 0 > ratios > fcf Percent
0.03547550231862625
Quarters > 0 > health Score
56
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
5469597000
Quarters > 1 > income Statement > cost Of Revenue
1317359000
Quarters > 1 > income Statement > gross Profit
4152238000
Quarters > 1 > income Statement > operating Expenses
4167423000
Quarters > 1 > income Statement > operating Income
-15185000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
313964000
Quarters > 1 > income Statement > net Income
297989000
Quarters > 1 > income Statement > eps
0.1825815439964897
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
1632087195
Quarters > 1 > income Statement > income Tax Expense
15975000
Quarters > 1 > income Statement > EBITDA
-231413000
Quarters > 1 > income Statement > operating Margin
-0.2776255727798593
Quarters > 1 > income Statement > total Other Income Expense Net
329149000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
7508185000
Quarters > 1 > balance Sheet > short Term Investments
375555000
Quarters > 1 > balance Sheet > receivables
1566930000
Quarters > 1 > balance Sheet > inventories
822167000
Quarters > 1 > balance Sheet > total Current Assets
10272837000
Quarters > 1 > balance Sheet > property Plant Equipment
5647242000
Quarters > 1 > balance Sheet > total Assets
21602602000
Quarters > 1 > balance Sheet > payables
357677000
Quarters > 1 > balance Sheet > short Term Debt
413929000
Quarters > 1 > balance Sheet > long Term Debt
2412354000
Quarters > 1 > balance Sheet > total Liabilities
8484873000
Quarters > 1 > balance Sheet > equity
13117729000
Quarters > 1 > balance Sheet > currency_symbol
CNY
Quarters > 1 > cash Flow > net Income
297989000
Quarters > 1 > cash Flow > depreciation
92140000
Quarters > 1 > cash Flow > change In Working Capital
568946000
Quarters > 1 > cash Flow > cash From Operations
1502658000
Quarters > 1 > cash Flow > capital Expenditures
266152000
Quarters > 1 > cash Flow > cash From Investing
-611722000
Quarters > 1 > cash Flow > cash From Financing
-345818000
Quarters > 1 > cash Flow > net Change In Cash
-1713957000
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
0.1825815439964897
Quarters > 1 > ratios > PB
1.4370328204104537
Quarters > 1 > ratios > ROE
2.271650832243904
Quarters > 1 > ratios > ROA
1.379412535582519
Quarters > 1 > ratios > FCF
1236506000
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.2260689407281743
Quarters > 1 > health Score
69
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
3952291000
Quarters > 2 > income Statement > cost Of Revenue
1094389000
Quarters > 2 > income Statement > gross Profit
2857902000
Quarters > 2 > income Statement > operating Expenses
3598589000
Quarters > 2 > income Statement > operating Income
-740687000
Quarters > 2 > income Statement > interest Expense
5274756
Quarters > 2 > income Statement > pretax Income
-392585000
Quarters > 2 > income Statement > net Income
-392620000
Quarters > 2 > income Statement > eps
-0.2419347140609866
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
1622834497
Quarters > 2 > income Statement > income Tax Expense
35000
Quarters > 2 > income Statement > EBITDA
-248864000
Quarters > 2 > income Statement > operating Margin
-18.7407000142449
Quarters > 2 > income Statement > total Other Income Expense Net
348102000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
8165264000
Quarters > 2 > balance Sheet > short Term Investments
463491000
Quarters > 2 > balance Sheet > receivables
1368940000
Quarters > 2 > balance Sheet > inventories
690411000
Quarters > 2 > balance Sheet > total Current Assets
11048658000
Quarters > 2 > balance Sheet > property Plant Equipment
5420865000
Quarters > 2 > balance Sheet > total Assets
20295696000
Quarters > 2 > balance Sheet > payables
220621000
Quarters > 2 > balance Sheet > short Term Debt
1011711000
Quarters > 2 > balance Sheet > long Term Debt
2270761000
Quarters > 2 > balance Sheet > total Liabilities
7869322000
Quarters > 2 > balance Sheet > equity
12426374000
Quarters > 2 > balance Sheet > currency_symbol
CNY
Quarters > 2 > cash Flow > net Income
-392620000
Quarters > 2 > cash Flow > depreciation
198670000
Quarters > 2 > cash Flow > change In Working Capital
-119127000
Quarters > 2 > cash Flow > cash From Operations
-215634000
Quarters > 2 > cash Flow > capital Expenditures
699513000
Quarters > 2 > cash Flow > cash From Investing
-553689000
Quarters > 2 > cash Flow > cash From Financing
-260814000
Quarters > 2 > cash Flow > net Change In Cash
-515868000
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.2419347140609866
Quarters > 2 > ratios > PB
1.508383575156357
Quarters > 2 > ratios > ROE
-3.159570120776986
Quarters > 2 > ratios > ROA
-1.934498821819168
Quarters > 2 > ratios > FCF
-915147000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-0.23154848668784764
Quarters > 2 > health Score
31
Quarters > 3 > quarter
2024-03-31
Quarters > 3 > income Statement > revenue
1976145500
Quarters > 3 > income Statement > cost Of Revenue
547194500
Quarters > 3 > income Statement > gross Profit
1428951000
Quarters > 3 > income Statement > operating Expenses
1799294500
Quarters > 3 > income Statement > operating Income
-370343500
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-196292500
Quarters > 3 > income Statement > net Income
-196310000
Quarters > 3 > income Statement > eps
-0.1209673570304933
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
1622834497
Quarters > 3 > income Statement > income Tax Expense
17500
Quarters > 3 > income Statement > EBITDA
-124432000
Quarters > 3 > income Statement > operating Margin
-18.7407000142449
Quarters > 3 > income Statement > total Other Income Expense Net
174051000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
-
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
-
Quarters > 3 > balance Sheet > property Plant Equipment
-
Quarters > 3 > balance Sheet > total Assets
-
Quarters > 3 > balance Sheet > payables
-
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
-
Quarters > 3 > balance Sheet > equity
-
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-196310000
Quarters > 3 > cash Flow > depreciation
99335000
Quarters > 3 > cash Flow > change In Working Capital
-59563500
Quarters > 3 > cash Flow > cash From Operations
-107817000
Quarters > 3 > cash Flow > capital Expenditures
349756500
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
-130407000
Quarters > 3 > cash Flow > net Change In Cash
-515868000
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.1209673570304933
Quarters > 3 > ratios > PB
-
Quarters > 3 > ratios > ROE
-
Quarters > 3 > ratios > ROA
-
Quarters > 3 > ratios > FCF
-457573500
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-0.23154848668784764
Quarters > 3 > health Score
32
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
9421888000
Annuals > 0 > income Statement > cost Of Revenue
1510210000
Annuals > 0 > income Statement > gross Profit
7911678000
Annuals > 0 > income Statement > operating Expenses
7653559000
Annuals > 0 > income Statement > operating Income
-755872000
Annuals > 0 > income Statement > interest Expense
67647000
Annuals > 0 > income Statement > pretax Income
-78621000
Annuals > 0 > income Statement > net Income
-94631000
Annuals > 0 > income Statement > eps
-0.05814640655262806
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
1627460846
Annuals > 0 > income Statement > income Tax Expense
16010000
Annuals > 0 > income Statement > EBITDA
-480277000
Annuals > 0 > income Statement > operating Margin
-8.022510987182187
Annuals > 0 > income Statement > total Other Income Expense Net
677251000
Annuals > 0 > income Statement > currency_symbol
CNY
Annuals > 0 > balance Sheet > cash
7508185000
Annuals > 0 > balance Sheet > short Term Investments
375555000
Annuals > 0 > balance Sheet > receivables
1566930000
Annuals > 0 > balance Sheet > inventories
822167000
Annuals > 0 > balance Sheet > total Current Assets
10272837000
Annuals > 0 > balance Sheet > property Plant Equipment
5647242000
Annuals > 0 > balance Sheet > total Assets
21602602000
Annuals > 0 > balance Sheet > payables
357677000
Annuals > 0 > balance Sheet > short Term Debt
413929000
Annuals > 0 > balance Sheet > long Term Debt
2412354000
Annuals > 0 > balance Sheet > total Liabilities
8484873000
Annuals > 0 > balance Sheet > equity
13117729000
Annuals > 0 > balance Sheet > currency_symbol
CNY
Annuals > 0 > cash Flow > net Income
-94631000
Annuals > 0 > cash Flow > depreciation
419768000
Annuals > 0 > cash Flow > change In Working Capital
449819000
Annuals > 0 > cash Flow > cash From Operations
1287024000
Annuals > 0 > cash Flow > capital Expenditures
1705412000
Annuals > 0 > cash Flow > cash From Investing
-1165411000
Annuals > 0 > cash Flow > cash From Financing
-606632000
Annuals > 0 > cash Flow > net Change In Cash
-472337000
Annuals > 0 > cash Flow > currency_symbol
CNY
Annuals > 0 > ratios > PE
-0.05814640655262806
Annuals > 0 > ratios > PB
1.3428876444317457
Annuals > 0 > ratios > ROE
-0.721397735842843
Annuals > 0 > ratios > ROA
-0.438053712233369
Annuals > 0 > ratios > FCF
-418388000
Annuals > 0 > ratios > Piotroski FScore
2
Annuals > 0 > ratios > fcf Percent
-0.04440596194732945
Annuals > 0 > health Score
32
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
6206070000
Annuals > 1 > income Statement > cost Of Revenue
1806844000
Annuals > 1 > income Statement > gross Profit
4399226000
Annuals > 1 > income Statement > operating Expenses
6078527000
Annuals > 1 > income Statement > operating Income
-1679301000
Annuals > 1 > income Statement > interest Expense
98624000
Annuals > 1 > income Statement > pretax Income
-1144411000
Annuals > 1 > income Statement > net Income
-1027913000
Annuals > 1 > income Statement > eps
-0.6590719490264159
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
1559637004
Annuals > 1 > income Statement > income Tax Expense
-116498000
Annuals > 1 > income Statement > EBITDA
-660684000
Annuals > 1 > income Statement > operating Margin
-27.059008357946336
Annuals > 1 > income Statement > total Other Income Expense Net
534890000
Annuals > 1 > income Statement > currency_symbol
CNY
Annuals > 1 > balance Sheet > cash
10052095000
Annuals > 1 > balance Sheet > short Term Investments
867534000
Annuals > 1 > balance Sheet > receivables
1005891000
Annuals > 1 > balance Sheet > inventories
968088000
Annuals > 1 > balance Sheet > total Current Assets
13427985000
Annuals > 1 > balance Sheet > property Plant Equipment
4656384000
Annuals > 1 > balance Sheet > total Assets
20627360000
Annuals > 1 > balance Sheet > payables
372549000
Annuals > 1 > balance Sheet > short Term Debt
1220330000
Annuals > 1 > balance Sheet > long Term Debt
2326777000
Annuals > 1 > balance Sheet > total Liabilities
8099779000
Annuals > 1 > balance Sheet > equity
12527581000
Annuals > 1 > balance Sheet > currency_symbol
CNY
Annuals > 1 > cash Flow > net Income
-1144411000
Annuals > 1 > cash Flow > depreciation
385103000
Annuals > 1 > cash Flow > change In Working Capital
403389000
Annuals > 1 > cash Flow > cash From Operations
147810000
Annuals > 1 > cash Flow > capital Expenditures
1383460000
Annuals > 1 > cash Flow > cash From Investing
-998662000
Annuals > 1 > cash Flow > cash From Financing
2587257000
Annuals > 1 > cash Flow > net Change In Cash
1729528000
Annuals > 1 > cash Flow > currency_symbol
CNY
Annuals > 1 > ratios > PE
-0.6590719490264159
Annuals > 1 > ratios > PB
1.3475475378124475
Annuals > 1 > ratios > ROE
-8.20519939164632
Annuals > 1 > ratios > ROA
-4.983250401408615
Annuals > 1 > ratios > FCF
-1235650000
Annuals > 1 > ratios > Piotroski FScore
2
Annuals > 1 > ratios > fcf Percent
-0.19910345838831983
Annuals > 1 > health Score
32
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
4556380000
Annuals > 2 > income Statement > cost Of Revenue
930990000
Annuals > 2 > income Statement > gross Profit
3625390000
Annuals > 2 > income Statement > operating Expenses
6207275000
Annuals > 2 > income Statement > operating Income
-3122846000
Annuals > 2 > income Statement > interest Expense
101698000
Annuals > 2 > income Statement > pretax Income
-2170469000
Annuals > 2 > income Statement > net Income
-2179270000
Annuals > 2 > income Statement > eps
-1.4624763990654002
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
1490123192
Annuals > 2 > income Statement > income Tax Expense
8801000
Annuals > 2 > income Statement > EBITDA
-1749349000
Annuals > 2 > income Statement > operating Margin
-68.53787436517587
Annuals > 2 > income Statement > total Other Income Expense Net
952377000
Annuals > 2 > income Statement > currency_symbol
CNY
Annuals > 2 > balance Sheet > cash
1016165000
Annuals > 2 > balance Sheet > short Term Investments
7248429000
Annuals > 2 > balance Sheet > receivables
911790000
Annuals > 2 > balance Sheet > inventories
1428882000
Annuals > 2 > balance Sheet > total Current Assets
11506708000
Annuals > 2 > balance Sheet > property Plant Equipment
4060719000
Annuals > 2 > balance Sheet > total Assets
17588845000
Annuals > 2 > balance Sheet > payables
325622000
Annuals > 2 > balance Sheet > short Term Debt
914392000
Annuals > 2 > balance Sheet > long Term Debt
2215433000
Annuals > 2 > balance Sheet > total Liabilities
6858896000
Annuals > 2 > balance Sheet > equity
10729949000
Annuals > 2 > balance Sheet > currency_symbol
CNY
Annuals > 2 > cash Flow > net Income
-2170469000
Annuals > 2 > cash Flow > depreciation
319422000
Annuals > 2 > cash Flow > change In Working Capital
309908000
Annuals > 2 > cash Flow > cash From Operations
-1918804000
Annuals > 2 > cash Flow > capital Expenditures
1381730000
Annuals > 2 > cash Flow > cash From Investing
-1435185000
Annuals > 2 > cash Flow > cash From Financing
2892082000
Annuals > 2 > cash Flow > net Change In Cash
-343243000
Annuals > 2 > cash Flow > currency_symbol
CNY
Annuals > 2 > ratios > PE
-1.4624763990654002
Annuals > 2 > ratios > PB
1.503184537988764
Annuals > 2 > ratios > ROE
-20.31016177243713
Annuals > 2 > ratios > ROA
-12.39006881918625
Annuals > 2 > ratios > FCF
-3300534000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-0.7243763689595688
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
4269729000
Annuals > 3 > income Statement > cost Of Revenue
573040000
Annuals > 3 > income Statement > gross Profit
3696689000
Annuals > 3 > income Statement > operating Expenses
5748665000
Annuals > 3 > income Statement > operating Income
-2703350000
Annuals > 3 > income Statement > interest Expense
62464000
Annuals > 3 > income Statement > pretax Income
-2641717000
Annuals > 3 > income Statement > net Income
-2728755000
Annuals > 3 > income Statement > eps
-1.874652527393044
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
1455605751
Annuals > 3 > income Statement > income Tax Expense
87038000
Annuals > 3 > income Statement > EBITDA
-2374506000
Annuals > 3 > income Statement > operating Margin
-63.31432275912593
Annuals > 3 > income Statement > total Other Income Expense Net
61633000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
1359408000
Annuals > 3 > balance Sheet > short Term Investments
6581485000
Annuals > 3 > balance Sheet > receivables
1181666000
Annuals > 3 > balance Sheet > inventories
1347240000
Annuals > 3 > balance Sheet > total Current Assets
11550849000
Annuals > 3 > balance Sheet > property Plant Equipment
3375757000
Annuals > 3 > balance Sheet > total Assets
16243713000
Annuals > 3 > balance Sheet > payables
195050000
Annuals > 3 > balance Sheet > short Term Debt
387273000
Annuals > 3 > balance Sheet > long Term Debt
2023261000
Annuals > 3 > balance Sheet > total Liabilities
5913316000
Annuals > 3 > balance Sheet > equity
10330397000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-2728755000
Annuals > 3 > cash Flow > depreciation
204747000
Annuals > 3 > cash Flow > change In Working Capital
-90283000
Annuals > 3 > cash Flow > cash From Operations
-2024843000
Annuals > 3 > cash Flow > capital Expenditures
1847516000
Annuals > 3 > cash Flow > cash From Investing
-2698148000
Annuals > 3 > cash Flow > cash From Financing
5003361000
Annuals > 3 > cash Flow > net Change In Cash
83230000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-1.874652527393044
Annuals > 3 > ratios > PB
1.525156937223613
Annuals > 3 > ratios > ROE
-26.41481251882188
Annuals > 3 > ratios > ROA
-16.798837802662483
Annuals > 3 > ratios > FCF
-3872359000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-0.9069332034890271
Annuals > 3 > health Score
30
Valuation > metrics > PE
108.24
Valuation > metrics > PB
1.3572221447050372
Valuation > final Score
50
Valuation > verdict
166.5% Overvalued
Profitability > metrics > ROE
5.7851297547743625
Profitability > metrics > ROA
6.372328947792518
Profitability > metrics > Net Margin
0.14014913925431044
Profitability > final Score
52
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.6360120983343295
Risk > metrics > Interest Coverage
5.839847200308015
Risk > final Score
71
Risk > verdict
Low
Liquidity > metrics > Current Ratio
8.464036388013831
Liquidity > metrics > Quick Ratio
7.734754987933799
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
100
Prev Valuations > 1
80
Prev Valuations > 2
50
Prev Profitabilities > 0
21
Prev Profitabilities > 1
0
Prev Profitabilities > 2
35
Prev Risks > 0
48
Prev Risks > 1
-514
Prev Risks > 2
9
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
50
Updated At
2026-01-20T22:03:35.100Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-24
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2021-03-31
Earnings History > 1 > report Date
2021-06-30
Earnings History > 1 > date
2021-03-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
CNY
Earnings History > 1 > eps Actual
-0.0628
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
-0.0628
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2020-12-31
Earnings History > 2 > report Date
2021-03-31
Earnings History > 2 > date
2020-12-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
CNY
Earnings History > 2 > eps Actual
-0.0618
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
-0.0618
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2020-09-30
Earnings History > 3 > report Date
2020-12-31
Earnings History > 3 > date
2020-09-30
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
CNY
Earnings History > 3 > eps Actual
-0.0218
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
-0.0218
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2020-06-30
Earnings History > 4 > report Date
2020-09-30
Earnings History > 4 > date
2020-06-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
CNY
Earnings History > 4 > eps Actual
-0.021
Earnings History > 4 > eps Estimate
0
Earnings History > 4 > eps Difference
-0.021
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2020-03-31
Earnings History > 5 > report Date
2020-06-30
Earnings History > 5 > date
2020-03-31
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
CNY
Earnings History > 5 > eps Actual
-0.0326
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
-0.0326
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2019-12-31
Earnings History > 6 > report Date
2020-03-31
Earnings History > 6 > date
2019-12-31
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
CNY
Earnings History > 6 > eps Actual
-0.0325
Earnings History > 6 > eps Estimate
0
Earnings History > 6 > eps Difference
-0.0325
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2019-09-30
Earnings History > 7 > report Date
2019-12-31
Earnings History > 7 > date
2019-09-30
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
CNY
Earnings History > 7 > eps Actual
-0.06
Earnings History > 7 > eps Estimate
0
Earnings History > 7 > eps Difference
-0.06
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2019-06-30
Earnings History > 8 > report Date
2019-09-30
Earnings History > 8 > date
2019-06-30
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
CNY
Earnings History > 8 > eps Actual
-0.0585
Earnings History > 8 > eps Estimate
0
Earnings History > 8 > eps Difference
-0.0585
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2019-03-31
Earnings History > 9 > report Date
2019-06-30
Earnings History > 9 > date
2019-03-31
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
CNY
Earnings History > 9 > eps Actual
-0.0452
Earnings History > 9 > eps Estimate
0
Earnings History > 9 > eps Difference
-0.0452
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2018-12-31
Earnings History > 10 > report Date
2019-03-31
Earnings History > 10 > date
2018-12-31
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
CNY
Earnings History > 10 > eps Actual
-0.0462
Earnings History > 10 > eps Estimate
0
Earnings History > 10 > eps Difference
-0.0462
Earnings History > 10 > surprise Percent
-
Earnings History > 11 > period
2018-09-30
Earnings History > 11 > report Date
2018-12-31
Earnings History > 11 > date
2018-09-30
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
CNY
Earnings History > 11 > eps Actual
-0.8074
Earnings History > 11 > eps Estimate
0
Earnings History > 11 > eps Difference
-0.8074
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2018-06-30
Earnings History > 12 > report Date
2018-09-30
Earnings History > 12 > date
2018-06-30
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
CNY
Earnings History > 12 > eps Actual
-0.8086
Earnings History > 12 > eps Estimate
0
Earnings History > 12 > eps Difference
-0.8086
Earnings History > 12 > surprise Percent
-
Earnings History > 13 > period
2018-03-31
Earnings History > 13 > report Date
2018-06-30
Earnings History > 13 > date
2018-03-31
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
CNY
Earnings History > 13 > eps Actual
-0.0886
Earnings History > 13 > eps Estimate
0
Earnings History > 13 > eps Difference
-0.0886
Earnings History > 13 > surprise Percent
-
Earnings History > 14 > period
2017-12-31
Earnings History > 14 > report Date
2018-03-31
Earnings History > 14 > date
2017-12-31
Earnings History > 14 > before After Market
-
Earnings History > 14 > currency
CNY
Earnings History > 14 > eps Actual
-0.0934
Earnings History > 14 > eps Estimate
0
Earnings History > 14 > eps Difference
-0.0934
Earnings History > 14 > surprise Percent
-
Earnings History > 15 > period
2017-09-30
Earnings History > 15 > report Date
2017-12-31
Earnings History > 15 > date
2017-09-30
Earnings History > 15 > before After Market
-
Earnings History > 15 > currency
CNY
Earnings History > 15 > eps Actual
-0.269
Earnings History > 15 > eps Estimate
0
Earnings History > 15 > eps Difference
-0.269
Earnings History > 15 > surprise Percent
-
Earnings History > 16 > period
2017-06-30
Earnings History > 16 > report Date
2017-09-30
Earnings History > 16 > date
2017-06-30
Earnings History > 16 > before After Market
-
Earnings History > 16 > currency
CNY
Earnings History > 16 > eps Actual
-0.2631
Earnings History > 16 > eps Estimate
0
Earnings History > 16 > eps Difference
-0.2631
Earnings History > 16 > surprise Percent
-
Earnings History > 17 > period
2017-03-31
Earnings History > 17 > report Date
2017-06-30
Earnings History > 17 > date
2017-03-31
Earnings History > 17 > before After Market
-
Earnings History > 17 > currency
CNY
Earnings History > 17 > eps Actual
-0.1755
Earnings History > 17 > eps Estimate
0
Earnings History > 17 > eps Difference
-0.1755
Earnings History > 17 > surprise Percent
-
Earnings History > 18 > period
2016-12-31
Earnings History > 18 > report Date
2017-03-31
Earnings History > 18 > date
2016-12-31
Earnings History > 18 > before After Market
-
Earnings History > 18 > currency
CNY
Earnings History > 18 > eps Actual
-0.1728
Earnings History > 18 > eps Estimate
0
Earnings History > 18 > eps Difference
-0.1728
Earnings History > 18 > surprise Percent
-
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverematinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), Dupert (fulzerasib), DOVBLERON (taletrectinib), Jaypirca (pirtobrutinib), limertinib, and SYCUME (teprotumumab N01 injection). The company is also developing three new drugs, which are under regulatory review; four assets in Phase 3 and pivotal clinical trials; and 15 molecules in early clinical stage. In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AWhat's Going On With Novo Nordisk Stock Monday? - Novo Nordisk (NYSE:NVO) Benzinga
Read more →Innovent inks $11.4 billion cancer drug partnership with Japan's Takeda (IVBIY:OTCMKTS) Seeking Alpha
Read more →Showing 2 of 5
(Last Updated 2025-06-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very Low
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Medium
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Innovent Biologics Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
2021-03-31
EPS Actual
-0.0628
EPS Estimate
0
EPS Difference
-0.0628
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.